SUIC Worldwide Holdings Ltd. (OTC Markets: SUIC) and VisionRenu Biomedical Technology Co., Ltd. have announced the signing of a Strategic Memorandum of Understanding (MOU) to collaborate in AI-powered biotechnology, precision medicine, and international capital market initiatives. The agreement, announced on June 29, 2026, establishes a framework that combines SUIC's expertise in business acceleration and capital market access with VisionRenu's medical technology innovations in brain health and ophthalmic devices.
The MOU aims to accelerate VisionRenu's global commercialization and create long-term value through strategic financing and potential U.S. capital market opportunities. Both companies view this as the first step toward a long-term strategic partnership focused on innovation and sustainable growth. VisionRenu, based in Taiwan, specializes in medical devices such as the MagRenu® Transcranial Magnetic Stimulation (TMS) System, approved by Taiwan's TFDA for depression treatment, and proprietary ophthalmic laser technologies. SUIC, a technology-enabled investment and business acceleration company, supports portfolio companies in expanding globally through strategic investments and access to international capital markets.
The collaboration enters the rapidly growing AI biotechnology sector, which is reshaping healthcare, drug discovery, synthetic biology, advanced manufacturing, and sustainable materials. AI enables faster gene editing, precision medicine, and DNA synthesis, significantly shortening development cycles for next-generation therapeutics. Industry analysts expect AI-enabled biotechnology to become one of the world's largest innovation markets, creating multi-trillion-dollar opportunities. SUIC's collaboration with VisionRenu, along with partnerships involving AI biotechnology startups supported by Taiwan's Ministry of Health and Welfare (MOHW), positions the company to expand into this sector. By leveraging AI, precision medicine, gene technologies, and international capital market resources, SUIC aims to accelerate innovation and build long-term shareholder value.
For more information about VisionRenu, visit https://www.vision-renu.com/. For more information about SUIC, visit https://sinounitedco.com/.
